AR053990A1 - Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion. - Google Patents

Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.

Info

Publication number
AR053990A1
AR053990A1 ARP050105253A ARP050105253A AR053990A1 AR 053990 A1 AR053990 A1 AR 053990A1 AR P050105253 A ARP050105253 A AR P050105253A AR P050105253 A ARP050105253 A AR P050105253A AR 053990 A1 AR053990 A1 AR 053990A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
pirazolpiridina
inhibitor
compact
factor
Prior art date
Application number
ARP050105253A
Other languages
English (en)
Inventor
Michael J Orwat
Mary F Malley
Roxana F Schlam
Steven R Fabian
Bing-Shiou Yang
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR053990A1 publication Critical patent/AR053990A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Composiciones farmacéuticas que comprenden dichos compuestos procesos de obtencion. Reivindicacion 1: La forma N-1 de 3-(1-hidroxi-1-metil-etil)-1-(4-metoxi-fenil)-6-[4-(2-oxo-2H-piridin-1-il)-fenil]-1,4,5,6-tetrahidro-pirazolo[3,4-c]piridin-7-ona cristalina, caracterizada porque parámetros celulares unitarios substancialmente iguales a los siguientes: dimensiones celulares a = 9.534 (1) amstrongs, b =9.842 (1), c = 13.469 (1) amstrongs, alfa = 87.95 (1), beta = 83.18 (1), gamma = 70.22 (1), grupo de espacio P-1 moléculas/unidad asimétrica 1 en donde la forma cristalina está a alrededor de +22 degree C.
ARP050105253A 2004-12-15 2005-12-14 Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion. AR053990A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR053990A1 true AR053990A1 (es) 2007-05-30

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105253A AR053990A1 (es) 2004-12-15 2005-12-14 Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.

Country Status (15)

Country Link
US (2) US7371864B2 (es)
EP (1) EP1828187A2 (es)
JP (1) JP2008524228A (es)
KR (1) KR20070087606A (es)
AR (1) AR053990A1 (es)
AU (1) AU2005317158A1 (es)
BR (1) BRPI0519331A2 (es)
CA (1) CA2589886A1 (es)
IL (1) IL183825A0 (es)
MX (1) MX2007006919A (es)
NO (1) NO20072666L (es)
PE (1) PE20060739A1 (es)
RU (1) RU2007126770A (es)
TW (1) TW200634011A (es)
WO (1) WO2006065853A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724638C (en) 2008-05-27 2020-02-18 Dako Denmark A/S Hybridization compositions and methods comprising a polar aprotic solvent
EP2401395A1 (en) 2009-02-26 2012-01-04 Dako Denmark A/S Compositions and methods for rna hybridization applications
US10662465B2 (en) 2011-09-30 2020-05-26 Agilent Technologies, Inc. Hybridization compositions and methods using formamide
US11118226B2 (en) 2011-10-21 2021-09-14 Agilent Technologies, Inc. Hybridization compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2726702A1 (en) * 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
US20080188517A1 (en) 2008-08-07
NO20072666L (no) 2007-09-07
JP2008524228A (ja) 2008-07-10
RU2007126770A (ru) 2009-01-27
PE20060739A1 (es) 2006-08-16
WO2006065853A2 (en) 2006-06-22
US7371864B2 (en) 2008-05-13
AU2005317158A1 (en) 2006-06-22
EP1828187A2 (en) 2007-09-05
CA2589886A1 (en) 2006-06-22
BRPI0519331A2 (pt) 2009-01-20
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
IL183825A0 (en) 2007-09-20
MX2007006919A (es) 2007-06-26
KR20070087606A (ko) 2007-08-28
WO2006065853A3 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
FR20C1036I1 (fr) Cellules precurseurs mesenchymateuses perivasculaires
DK1894564T3 (da) Anvendelse af en IBAT inhibitor til behandling eller profylakse af konstipation
RS53638B1 (en) CRYSTAL SOLVATES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLUCITOL WITH ALCOHOLS AS INHIBITORS OF SGLT2 FOR TREATMENT OF DIABETES
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
UY28513A1 (es) Nuevos compuestos
AR053990A1 (es) Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.
DK1644398T3 (da) Specifik glucocorticosteroidforbindelse med antiinflammatorisk aktivitet
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
WO2004016548A3 (en) Aluminum phosphate compounds, compositions, materials and related composites.
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
EP1740183B8 (en) Novel use for pde5 inhibitors
BRPI0509154A (pt) composição quìmica e usos
SE0302324D0 (sv) Novel compounds
MX2007011493A (es) Modalidades antiinflamatorias.
NO20085317L (no) Imidazoazepinonforbindelser
ATE366714T1 (de) Verwendung von mehrfach modifiziertem zeolith in der biogasgewinnung
DE602004007625D1 (de) Dram-ausgangsschaltkreise zur unterstützung der sequenziellen datenerfassung zur verringerung von kernzugriffszeiten
CN206350698U (zh) 一种卫生间用多功能置物架
AR046131A1 (es) Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona
DE602004017450D1 (de) Verbesserungen in der verwendung von brennstoff in elektrochemischen brennstoffzellen
DE60315448D1 (de) 1-azadibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
DE60324250D1 (de) Inhibitoren der alpha-l-beta-2-integrinvermittelten zelladhäsion
DE602005007270D1 (de) HETEROARYLACETAMIDE ALS FAKTOR Xa INHIBITOREN
DE60323748D1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produfür deren herstellung

Legal Events

Date Code Title Description
FB Suspension of granting procedure